At this time, posts about HanAll Biopharma are rapidly increasing on portals and securities communities. Today, foreigners have net sold 54,000 shares of HanAll Biopharma, while institutions have net bought 12,000 shares, according to provisional data. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.


As of 11:30 AM on the 3rd, HanAll Biopharma's stock price is 38,150 KRW, up 4.95% from the previous day, with a trading volume of 3,342,331 shares, which is 202.01% of the 5-day average trading volume. On August 26, HanAll Biopharma became a market issue with the headline "3%↑ on success of Phase 2 clinical trial of antibody drug by US partner."


In addition to HanAll Biopharma, posts by investors are also rapidly increasing for Ilsin Bio (068330), Newgelab (214870), and Wooshin System (017370).


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

※Source: AI Investment Assistant AI Lassiro


※ This article was generated in real time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing